即時分子診斷市場規模、佔有率和成長分析：按技術、疾病、最終用戶和地區分類－2026-2033年產業預測

2024 年全球即時分子診斷市場價值為 85.2 億美元，預計到 2033 年將從 2025 年的 95 億美元成長至 228.5 億美元，在預測期（2026-2033 年）內複合年成長率為 11.52%。

全球即時分子診斷市場正經歷顯著成長，這主要得益於快速、精準檢測解決方案日益成長的需求。這些解決方案能夠在患者現場直接進行DNA和RNA分析，從而簡化決策流程。微流體、試劑穩定性和樣本製備技術的進步，已將笨重的實驗室PCR設備轉變為攜帶式設備。監管政策的調整和報銷機制的完善至關重要，它們刺激了製造商對產品研發的投資，並推動了這些技術在醫療機構中的應用。此外，人工智慧透過先進的訊號處理、自動化品管和臨床決策支援系統，提高了檢測的準確性和速度，從而正在改變這一領域。這些分散式檢查趨勢有望促進分子診斷的普及，並使其在急診和臨床環境中得到更廣泛的應用。

全球即時分子診斷市場促進因素

全球即時分子診斷市場的主要促進因素之一是對快速、精準診斷工具日益成長的需求，尤其是在應對感染疾病和新出現的健康危機方面。隨著醫療機構轉向更加分散的檢測方案，對能夠實現及時治療的快速診斷的需求變得至關重要。分子技術的不斷進步進一步強化了這一需求，這些技術縮短了檢測反應時間，同時提高了檢測的靈敏度和特異性。此外，慢性病盛行率的上升以及人們對個人化醫療意識的提高也促進了市場擴張，推動了即時診斷解決方案的普及。

全球即時分子診斷市場面臨的限制因素

全球即時分子診斷市場的主要限制因素之一是先進診斷技術的研發和應用高成本。這些先進設備通常需要大量的研發投入、監管核准和品管措施，這可能成為普及應用的障礙，尤其是在低收入地區。此外，這些檢測的複雜性可能需要醫護人員接受專門培訓，這進一步阻礙了其廣泛應用。因此，這些財務和營運方面的障礙會阻礙市場成長和創新，並可能限制即時分子診斷在各種醫療機構中的普及。

全球即時分子診斷市場趨勢

全球即時分子診斷市場正經歷顯著的去中心化轉型，這主要得益於患者對便捷易用的檢測方式日益成長的需求。這項轉變凸顯了簡化決策流程和提升使用者體驗對醫護人員和病患的重要性。為此，製造商正在開發攜帶式設備，以簡化檢體處理，並通常配備全面的培訓材料，供檢查室人員使用。此外，保險公司日益重視透過快速診斷來實現價值最大化，這也加速了這一轉型，使去中心化的分子檢測成為現代醫療生態系統的重要組成部分，有助於提高效率並改善患者預後。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球即時分子診斷市場規模：依技術分類

• 基於PCR的
• 等溫擴增（LAMP）
• CRISPR 基礎
• 微陣列

全球即時分子診斷市場規模：依疾病分類

• 呼吸道感染疾病
• 性行為感染感染（STI）
• 敗血症
• 抗菌素抗藥性

全球即時分子診斷市場規模：依最終用戶分類

• 醫院
• 基層醫療診所
• 藥局
• 家庭測試

全球即時分子診斷市場規模：按地區分類

• 北美洲
• 歐洲
• 亞太地區

全球即時分子診斷市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Roche（cobas Liat）
• Cepheid（Danaher）
• Abbott（ID NOW）
• bioMerieux（BioFire）
• Hologic（Panther Fusion）
• Becton Dickinson（BD MAX）
• GenMark Diagnostics（Roche）
• Diasorin Molecular
• Qiagen NV
• Luminex（DiaSorin）
• Talis Biomedical
• Mammoth Biosciences
• Sherlock Biosciences
• Lucira Health（Pfizer）
• LumiraDx
• BioFire Defense
• Meso Scale Diagnostics
• Genetic Signatures
• Primerdesign（Novacyt）
• IsoAmp Molecular

結論與建議

Global Point-Of-Care Molecular Diagnostics Market size was valued at USD 8.52 Billion in 2024 and is poised to grow from USD 9.5 Billion in 2025 to USD 22.85 Billion by 2033, growing at a CAGR of 11.52% during the forecast period (2026-2033).

The Global Point-Of-Care Molecular Diagnostics market is witnessing significant growth due to the increasing demand for rapid and accurate testing solutions that provide DNA and RNA analysis directly at the patient site, thereby streamlining decision-making processes. Technological advancements in microfluidics, reagent stabilization, and sample preparation have evolved bulky laboratory PCR devices into portable formats. Factors such as regulatory alignment and reimbursement clarity are crucial, as they drive investments in product development by manufacturers and enhance healthcare facilities' adoption of these technologies. Furthermore, AI is transforming this landscape by improving test accuracy and speed through advanced signal processing, automated quality control, and clinical decision support systems. This trend towards decentralized testing promises easier implementation and broader accessibility to molecular diagnostics in both emergency and clinical settings.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Point-Of-Care Molecular Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Point-Of-Care Molecular Diagnostics Market Segments Analysis

Global point-of-care molecular diagnostics market is segmented by technology, disease, end-user and region. Based on technology, the market is segmented into PCR-Based, Isothermal Amplification (LAMP), CRISPR-Based and Microarray. Based on disease, the market is segmented into Respiratory Infections, STIs, Sepsis and Antibiotic Resistance. Based on end-user, the market is segmented into Hospitals, Primary Care Clinics, Pharmacies and Home Testing. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Point-Of-Care Molecular Diagnostics Market

One of the key market drivers for the global point-of-care molecular diagnostics market is the increasing demand for rapid and accurate diagnostic tools, particularly in response to infectious diseases and emerging health crises. As healthcare providers shift towards more decentralized testing solutions, the need for prompt diagnosis to facilitate timely treatment becomes paramount. This demand is amplified by the ongoing advancements in molecular technologies, which enhance the sensitivity and specificity of tests while reducing turnaround times. Additionally, the growing prevalence of chronic diseases and rising awareness of personalized medicine further contribute to the market's expansion, driving greater adoption of point-of-care solutions.

Restraints in the Global Point-Of-Care Molecular Diagnostics Market

One of the key market restraints for the global point-of-care molecular diagnostics market is the high cost associated with the development and implementation of advanced diagnostic technologies. These sophisticated devices often require significant investment in research and development, regulatory approvals, and quality control measures, which can limit accessibility, particularly in low-income regions. Additionally, the complexity of these tests may demand specialized training for healthcare personnel, leading to further challenges in widespread adoption. Consequently, these financial and operational barriers may hinder market growth and innovation, restricting the availability of point-of-care molecular diagnostics in various healthcare settings.

Market Trends of the Global Point-Of-Care Molecular Diagnostics Market

The Global Point-Of-Care Molecular Diagnostics market is witnessing a significant trend towards decentralization, driven by an increasing demand for accessible and convenient testing options close to patients. This shift emphasizes the importance of streamlined decision-making and user-friendly processes for both healthcare providers and patients. Manufacturers are responding by innovating portable devices that simplify sample handling, often accompanied by comprehensive training materials aimed at non-laboratory personnel. Furthermore, the growing interest from payers in maximizing value from rapid diagnostics is accelerating this transition, positioning decentralized molecular testing as a vital component of modern healthcare ecosystems, enhancing efficiency and patient outcomes.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Point-of-Care Molecular Diagnostics Market Size by Technology & CAGR (2026-2033)

• Market Overview
• PCR-Based
• Isothermal Amplification (LAMP)
• CRISPR-Based
• Microarray

Global Point-of-Care Molecular Diagnostics Market Size by Disease & CAGR (2026-2033)

• Market Overview
• Respiratory Infections
• STIs
• Sepsis
• Antibiotic Resistance

Global Point-of-Care Molecular Diagnostics Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Primary Care Clinics
• Pharmacies
• Home Testing

Global Point-of-Care Molecular Diagnostics Market Size by Region & CAGR (2026-2033)

• Market Overview
• North America
• Europe
• Asia-Pacific

Global Point-of-Care Molecular Diagnostics Market Size & CAGR (2026-2033)

• North America (Technology, Disease, End-User, Region)
  • US
  • Canada
• Europe (Technology, Disease, End-User, Region)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Technology, Disease, End-User, Region)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Technology, Disease, End-User, Region)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Technology, Disease, End-User, Region)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Roche (cobas Liat)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cepheid (Danaher)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott (ID NOW)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux (BioFire)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic (Panther Fusion)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton Dickinson (BD MAX)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GenMark Diagnostics (Roche)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Diasorin Molecular
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qiagen NV
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Luminex (DiaSorin)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Talis Biomedical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mammoth Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sherlock Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lucira Health (Pfizer)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LumiraDx
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioFire Defense
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Meso Scale Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genetic Signatures
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Primerdesign (Novacyt)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IsoAmp Molecular
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations